GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASLAN Pharmaceuticals Ltd (NAS:ASLN) » Definitions » Interest Expense

ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Interest Expense : $-3.92 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ASLAN Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ASLAN Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was $ -0.67 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.92 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ASLAN Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $ -9.29 Mil. ASLAN Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $ -0.67 Mil. ASLAN Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


ASLAN Pharmaceuticals Interest Expense Historical Data

The historical data trend for ASLAN Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASLAN Pharmaceuticals Interest Expense Chart

ASLAN Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.90 -1.25 -1.86 -3.67 -4.33

ASLAN Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.08 -1.13 -1.13 -0.99 -0.67

ASLAN Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ASLAN Pharmaceuticals  (NAS:ASLN) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ASLAN Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $-0.67 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-9.29 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $19.35 Mil.

ASLAN Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

ASLAN Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
3 Temasek Avenue, Level 18, Centennial Tower, Singapore, SGP, 039190
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.

ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Headlines

From GuruFocus